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Background—In the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation 
(ARISTOTLE) trial, apixaban compared with warfarin reduced stroke and systemic embolism, major bleeding, and 
mortality. We evaluated treatment effects in relation to 2 predictions of time in therapeutic range (TTR).
Methods and Results—The trial randomized 18 201 patients with atrial fibrillation to apixaban 5 mg twice daily or warfarin 
for at least 12 months. For each patient, a center average TTR was estimated with the use of a linear mixed model on 
the basis of the real TTRs in its warfarin-treated patients, with a fixed effect for country and random effect for center. 
For each patient, an individual TTR was also predicted with the use of a linear mixed effects model including patient 
characteristics as well. Median center average TTR was 66% (interquartile limits, 61% and 71%). Rates of stroke or 
systemic embolism, major bleeding, and mortality were consistently lower with apixaban than with warfarin across 
center average TTR and individual TTR quartiles. In the lowest and highest center average TTR quartiles, hazard ratios 
for stroke or systemic embolism were 0.73 (95% confidence interval [CI], 0.53–1.00) and 0.88 (95% CI, 0.57–1.35) 
(Pinteraction=0.078), for mortality were 0.91 (95% CI, 0.74–1.13) and 0.91 (95% CI, 0.71–1.16) (Pinteraction=0.34), and for 
major bleeding were 0.50 (95% CI, 0.36–0.70) and 0.75 (95% CI, 0.58–0.97) (Pinteraction=0.095), respectively. Similar 
results were seen for quartiles of individual TTR.
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Warfarin and other vitamin K antagonists effectively prevent stroke in patients with atrial fibrillation (AF), 
but they have a narrow therapeutic window with an increased 
risk of stroke and bleeding when above or below the thera-
peutic range of the international normalized ratio (INR) of 2.0 
to 3.0.1–3 The dose response is influenced by several factors 
such as age, body weight, genetic variation, food, and come-
dications. Regular INR-guided dose adjustments are therefore 
necessary.1–3 However, there are large variations of the time in 
therapeutic range (TTR) across individuals, sites, and coun-
tries, and these variations are related to patient outcomes.4–9 
Several trials have shown recently that the quality of warfarin 
use, as measured with INR control at the center or country 
level, may interact with the treatment effects of new anti-
thrombotic treatments when compared with warfarin.10–12
Editorial see p 2163
Clinical Perspective on p 2176
Apixaban is a new oral direct factor Xa inhibitor providing sta-
ble anticoagulation at a fixed dose twice daily without the need 
for anticoagulation monitoring. In the prospective, randomized, 
and double-blind Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) 
trial including 18 201 patients with AF and at least 1 additional 
risk factor for stroke, apixaban 5 mg twice daily reduced stroke 
or systemic embolism, major bleeding, and mortality compared 
with warfarin with a median TTR of 66%.13,14 On the basis of 
previous reports of interactions between treatment effects of 
novel antithrombotic strategies and the quality of INR control in 
the warfarin arm,10–12 we evaluated the influence of participating 
centers’ and patients’ predicted quality of INR control on the 
effects of apixaban compared with warfarin on key clinical out-
come events in this trial. Given the limited information available 
to a physician at the time of treatment selection, a prediction 
of INR integrating knowledge of the country and center perfor-
mance in terms of INR control and the individual patient history 
will provide the best available means to identify those who will 
have better or worse outcomes on warfarin. Hence, the present 
study of treatment interactions with predicted TTR will deter-
mine whether such information is useful in the decision to prefer 
warfarin or apixaban in different patients or treatment settings.
Methods
Patients
The ARISTOTLE trial was a double-blind, double-dummy, random-
ized trial comparing apixaban 5 mg twice daily (or 2.5 mg twice 
daily for patients with at least 2 of the following 3 criteria: age ≥80 
years, body weight ≤60 kg, or serum creatinine level ≥1.5 mg/dL 
[133 μmol/L]) with warfarin in patients with AF at risk for stroke. 
The design and main results have been published previously.13,14 In 
brief, inclusion criteria were documented AF and ≥1 of the following 
risk factors for stroke: age ≥75 years; prior stroke, transient ischemic 
attack, or systemic embolism; symptomatic heart failure within 3 
months or systolic dysfunction with a left ventricular ejection fraction 
≤40%; diabetes mellitus; and hypertension requiring pharmacologi-
cal treatment. Reasons for exclusion included AF due to a reversible 
cause; mitral stenosis; prosthetic heart valve or other indication for 
oral anticoagulation; need for aspirin in a dose >165 mg/d or in com-
bination with clopidogrel; recent stroke (<7 days); increased risk of 
hemorrhage; anemia with hemoglobin <9 g/dL; creatinine clearance 
<25 mL/min; active liver disease; other comorbid condition with 
reduced life expectancy; and inability to comply with INR monitor-
ing or other study procedures. Institutional review board approval and 
patient written informed consent were obtained before enrollment.
Randomization and Masking
Randomization was stratified by center and prior warfarin use status 
(naive or experienced, determined on the basis of whether warfarin or 
other vitamin K antagonists had been used previously for >30 con-
secutive days). Recruitment was monitored with the goal of including 
≈40% warfarin-naive patients at all sites. Apixaban (or correspond-
ing placebo) was supplied in tablets taken twice daily. Warfarin (or 
matching placebo) was provided as 2-mg tablets dosed by the inves-
tigator to achieve a target INR of 2.0 to 3.0. Patients who were tak-
ing vitamin K antagonists before randomization were instructed to 
discontinue the drug 3 days before randomization and were not dosed 
until the INR was <2.0. To maintain blinding, INRs were monitored 
with the use of an encrypted point-of-care INR device that provided a 
number to enter into the interactive voice recognition system that then 
presented the real INR for the patients on blinded warfarin or a sham 
INR for patients on warfarin placebo. During the titration phase, we 
recommended the use of a dosing algorithm with initial daily dose 
of up to 6 mg of warfarin (or warfarin placebo), unless the patient 
was previously on a stable dose of warfarin, in which case that dose 
might be resumed. Subsequent warfarin doses were recommended 
on the basis of an algorithm provided to the investigators; however, 
the final dose decision was left to the discretion of the investigator. 
INRs were monitored on day 4, twice a week for 2 weeks, once a 
week for 2 weeks, and monthly thereafter once a stable INR was ob-
tained. Additional INR measurements were encouraged if clinically 
indicated. TTR was calculated by the method of Rosendaal.15–17 A 
program seeking to improve the quality of INR control in the warfa-
rin-treated patients included education, instructions, and feedback on 
INR control at the national and site levels. An algorithm was provided 
to manage temporary discontinuations in a blinded fashion.
Follow-Up and Clinical Outcomes
Patients were followed at monthly intervals after randomization and 
monthly thereafter until the study end. The primary efficacy outcome 
was stroke (ischemic, hemorrhagic, or unspecified) or systemic em-
bolism. The primary safety outcome was International Society on 
Thrombosis and Hemostasis major bleeding. All-cause death was a 
key secondary outcome. Other predefined outcomes were the com-
posites of stroke or systemic embolism and major bleeding and, as 
net clinical benefit, the composite of stroke or systemic embolism, 
all-cause death, and major bleeding. All primary and secondary effi-
cacy and safety outcome events were adjudicated by a blinded clinical 
events committee using prespecified criteria and coordinated by the 
Duke Clinical Research Institute or Uppsala Clinical Research Center.
Conclusions—The benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality 
appear similar across the range of centers’ and patients’ predicted quality of international normalized ratio control. 
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984. (Circulation. 
2013;127:2166-2176.)
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Statistical Analysis
The quality of INR control was quantified for all participating sites. First 
we calculated TTR for each individual warfarin-treated patient, during 
the entire treatment period, by the Rosendaal interpolation method.15–17 
We excluded INR levels during the first 7 days after randomization, 
during warfarin treatment interruptions, and beyond 2 days after the 
last dose of warfarin. Patients with <2 INR levels were excluded. 
Subsequently, each center’s average TTR (cTTR) was estimated with 
the use of a linear mixed model for TTR in warfarin-treated patients, 
including a fixed effect for country and random effect for center. The TTR 
was transformed by a square root transformation to improve normality, 
and subjects were weighted according to the number of INR values that 
contributed to their TTR to reflect the greater variability that is likely 
to occur with fewer measurements. The cTTR was then predicted from 
the model with the use of empirical Bayes estimates of center effects 
and transformed back to the natural scale. The mixed model is designed 
to address the problem of measurement error, in which small sites will 
have greater variability in estimated TTR than large sites. The current 
approach is akin to regression calibration, a standard measurement error 
method. Thereafter, individual patient characteristics were added to 
the model and used to estimate individual patient–level predicted TTR 
(iTTR). Both models for TTR were fit on patients from the warfarin arm, 
and these models were used to obtain predictions for all patients based 
on their center (cTTR) and individual patient characteristics (iTTR). For 
both models, we report the likelihood ratio R2 for mixed models.
In the analysis of outcome in relation to cTTR, the center’s cTTR 
values were assigned to all patients representing the center’s predicted 
quality of INR control during the trial. Similarly, iTTR was applied 
as an estimate of the individual quality of INR control that could be 
expected given a patient’s center and baseline characteristics, regard-
less of study treatment. To address the primary hypothesis of effect 
modification according to predicted quality of INR control, we tested 
for an interaction between continuous cTTR or iTTR and treatment in 
a Cox regression model for outcome, including all patients. We did not 
assume linearity in testing this interaction but instead fitted a restricted 
cubic spline to cTTR and iTTR, respectively. In sensitivity analyses, 
we accounted for correlation between patients within the same center 
by using the empirical sandwich variance, and results were unchanged. 
The following outcomes were evaluated in these analyses: stroke or 
systemic embolism (primary efficacy outcome), major bleeding (pri-
mary safety outcome), total mortality, and the composite outcomes.
To simplify the description of patient characteristics and potential treat-
ment interactions, centers (or patients) were then arranged in ascending 
quartiles of cTTR and iTTR. The interquartile cutoff limits were identi-
fied to keep the patient numbers within each quartile approximately bal-
anced. Even when a statistically significant interaction was not present, 
the outcomes were presented across the 4 groups defined by the quartiles 
of cTTR and iTTR. The results are presented as hazard ratios (HRs) with 
95% confidence intervals (CIs). Baseline characteristics are compared 
across quartiles of predicted TTR with the use of the Kruskal-Wallis test 
for continuous variables and χ2 tests for categorical variables. Continuous 
variables are presented as medians and 25th and 75th percentiles unless 
otherwise stated, and categorical variables are presented as counts and 
percentages. Two-sided α of 0.05 was used to determine statistical sig-
nificance, although P values were not corrected for multiple testing.
Additional analyses were performed to describe the variability in 
INR across countries. In addition to the individual proportion of time 
in therapeutic range (iTTR), we calculated the individual proportions 
of time below range (INR <2) and time above range (INR >3). We 
described country INR control by calculating the median iTTR, time 
below range, and time above range among all warfarin-treated pa-
tients within a country and comparing these across countries.
These statistical analyses were performed at Duke Clinical 
Research Institute with the use of SAS software version 9.0 (SAS 
Institute, Inc, Cary, NC).
Results
The study randomized 18 201 patients from 1034 clini-
cal centers in 39 countries. A total of 268 013 INR values 
corresponding to an average of 1.47 INR values per patient 
per month were collected during a median follow-up of 1.8 
years.
Variation in TTR
The median (interquartile range) of TTR in the patients in the 
warfarin arm was 66.0% (52.4% to 76.5%). Countries exhib-
ited substantial variation in INR control, with median TTR 
ranging from 46% to 80% (Figure 1). This was mainly driven 
by variability in the time below therapeutic range (INR <2.0), 
which ranged from 9% to 47%. Time above therapeutic range 
(INR >3.0) was more constant, with a range from 5% to 16% 
across countries. Variation was also observed between centers 
within a country, but the country differences were larger (Fig-
ure I in the online-only Data Supplement).
Predicted cTTR and iTTR
The median of predicted cTTR in the patients in the warfa-
rin arm was 66.4%, with an interquartile range from 60.6% 
to 71.2%. The model for cTTR explained 29.6% (correlation 
coefficient 0.54) of the variability in iTTR. As expected, for 
iTTR there was a variability similar to that for cTTR among and 
within countries (Figure I in the online-only Data Supplement).
The median of predicted iTTR in the patients in the war-
farin arm was 66.0%, with an interquartile range from 60.0% 
to 71.2%. In addition to center, the estimation of iTTR was 
based on the following characteristics related to iTTR in the 
warfarin group: country, age, sex, body weight, race, hyper-
tension, smoking, diabetes mellitus, congestive heart failure, 
prior stroke, statin use, insulin use, vitamin K antagonist treat-
ment experience, and amiodarone use. This model explained 
29.9% of the variability in iTTR, which was only 0.3% more 
than that in the center-level model. The predictions of iTTR 
from this model had a correlation of 0.97 with cTTR (Figure 
II in the online-only Data Supplement).
Baseline Characteristics
When we compared the populations within the different quar-
tiles of cTTR and iTTR, there were, as expected, several sig-
nificant differences in baseline characteristics (Tables 1 and 2). 
However, because the randomization to the investigational 
treatment groups was stratified by center, these were well bal-
anced between the treatment groups within each of the quar-
tiles on the basis of cTTR or iTTR.
Clinical Outcomes in Relation to Predicted TTR
In the total population, the primary outcome of stroke or 
systemic embolism was 1.27% per year in the apixaban 
group and 1.60% per year in the warfarin group (HR=0.79 
[95% CI, 0.66–0.95]). The treatment effect was maintained 
across different levels of predicted cTTR without any clear 
directional interaction, with HR=0.73 (95% CI, 0.53–1.00) 
in the lowest and HR=0.88 (95% CI, 0.57–1.35) (interaction 
with continuous cTTR, P=0.078) in the highest cTTR 
quartiles, respectively (Figures 2 and 3). The results were 
similar across different levels of predicted iTTR, with 
HR=0.70 (95% CI, 0.52–0.94) in the lowest and HR=0.87 
(95% CI, 0.57–1.33) (interaction with continuous iTTR, 
P=0.060) in the highest iTTR quartiles, respectively 
 by guest on June 28, 2017
http://circ.ahajournals.org/
D
ow
nloaded from
 
Wallentin et al  Apixaban in Relation to Predicted INR Control  2169
Figure 1. Country distribution of percentage of time in therapeutic range (TTR) of 2.0 to 3.0, percentage of time above treatment range 
(>3.0), and percentage of time below treatment range (<2.0) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation (ARISTOTLE) trial. ARGEN indicates Argentina; AUS, Austria; AUSTL, Australia; BELG, Belgium; BRAZ, Brazil;  
CAN, Canada; COLOM, Colombia; CZR, Czech Republic; DEN, Denmark; FIN, Finland; FRA, France; GER, Germany; HKONG, Hong 
Kong; HUN, Hungary; IND, India; INR, international normalized ratio; ISR, Israel; MALAY, Malaysia; MEX, Mexico; NETH, Netherlands; 
NOR, Norway; PHIL, Phillipines; POL, Poland; PRICO, Puerto Rico; ROMAN, Romania; RUSS, Russia; SAFR, South Africa; SING, 
Singapore; SWE, Sweden; TAIW, Taiwan; TURK, Turkey; and UKR, Ukraine.
(Figure 4). When the predicted TTR subgroups were further 
divided into patients with and without vitamin K antagonist 
treatment within 30 days of randomization, the results 
became more variable, probably because of chance due to 
low numbers of events in several subgroups (Tables I and II 
in the online-only Data Supplement).
In the overall study, total mortality was 3.52% per year with 
apixaban versus 3.94% per year with warfarin (HR=0.89 [95% 
CI, 0.80–0.99]). With regard to mortality, the treatment effect 
was identical in the lowest (HR=0.91 [95% CI, 0.74–1.13]) 
and highest (HR=0.91 [95% CI, 0.71–1.16]) cTTR quartiles 
(interaction with continuous cTTR, P=0.34) (Figures 2 and 
3). The results were similar in relation to iTTR (Figure 4). 
These results were also consistent when the TTR subgroups 
were subdivided on the basis of previous vitamin K antagonist 
 treatment (Tables I and II in the online-only Data Supplement).
In the overall study, major bleeding was substantially lower 
with apixaban (2.13% per year) than with warfarin (3.09% 
per year) (HR=0.69 [95% CI, 0.60–0.80]). There were sub-
stantial benefits of apixaban over warfarin across the range 
of cTTR, with HR for apixaban versus warfarin of 0.50 (95% 
CI, 0.36–0.70) in the lowest and 0.75 (95% CI, 0.58–0.97) 
in the highest cTTR quartiles (interaction with continuous 
cTTR, P=0.095) (Figures 2 and 3). The results were consis-
tent in relation to iTTR, with HR=0.48 (95% CI, 0.35–0.67) 
in the lowest and 0.73 (95% CI, 0.55–0.94) in the highest 
iTTR quartiles (interaction with continuous iTTR, P=0.078) 
(Figure 4). These results were also consistent when the TTR 
subgroups were subdivided on the basis of previous vitamin 
K antagonist  treatment (Tables I and II in the online-only Data 
Supplement).
We also analyzed the relations between the cTTR and iTTR 
quartiles, respectively, and the prespecified net clinical benefit 
(composite of stroke, systemic embolism, all-cause death, and 
major bleeding) and the composite of stroke, systemic embo-
lism, and major bleeding. Regardless of cTTR or iTTR quar-
tile, there were consistent benefits with apixaban compared 
with warfarin, with HR in the range of 0.61 to 0.92 and interac-
tion P values between 0.32 and 0.85 (Figures 3 and 4). In addi-
tion, these results were consistent when the TTR subgroups 
were subdivided on the basis of previous vitamin K antagonist 
treatment (Tables I and II in the online-only Data Supplement).
Discussion
In the overall ARISTOTLE trial, apixaban, compared with 
warfarin, reduced the risk of stroke or systemic embolism, 
caused less major bleeding, and reduced mortality. The 
present complementary analyses showed that the reduction in 
the primary efficacy outcome of stroke or systemic embolism 
with apixaban was maintained across the broad range of 
centers’ and patients’ predicted quality of INR control. In 
addition, there was no significant interaction between the 
quality of INR control and the reduction of mortality. The 
reduction in major bleeding in patients receiving apixaban 
was also maintained regardless of centers’ and patients’ 
predicted TTR, although the magnitude of these benefits 
seemed to be attenuated in patients and centers with better 
expected INR control. When all major events were combined 
(ie, stroke, systemic embolism, all-cause death, and major 
bleeding), there was a consistent benefit with apixaban 
throughout the range of predicted TTR. These findings 
indicate similar benefits of apixaban versus warfarin for 
preventing stroke and reducing bleeding and all-cause 
mortality regardless of the expected quality of INR control 
with warfarin that can be achieved at different centers or for 
different patients.
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In this double-blind trial, the median TTR in the warfarin 
group was 66%. This overall standard of INR control seems 
better than in usual clinical practice, which often reports lower 
TTR.18–21 However, in sites and countries with a more optimal 
anticoagulation service, even better results can be achieved.22 
The median TTR in ARISTOTLE was similar to that observed 
in several previous open-label warfarin controlled trials10,11,23 
and higher than that observed in a previous double-blind 
trial.24 The comparison of TTR across trials is associated 
with several sources of bias, including standardization of INR 
measurements, blinding and completeness of reporting of INR 
results, frequency of INR monitoring, method for calculating 
TTR, and participating countries, sites, and population studied.
The variability in the quality of warfarin use has led to 
questions of how to interpret the overall findings for countries 
and sites with different standards of INR control.11,12 In the 
absence of any indicator of anticoagulation status for patients 
in the apixaban group, the currently used models for evalu-
ation of treatment effects in relation to statistically based 
predictions of TTR at trial entry represent further develop-
ments of previous methods to address this issue. In real-life 
healthcare situations, treatment decisions will be based on an 
integration of available information at the start of treatment. 
Therefore, a prediction of TTR seems to represent the best 
utilization of available information, at baseline, toward esti-
mating outcomes while patients are on warfarin treatment. To 
this end, our first alternative was to base the prediction on the 
expected TTR in the center where the patient was random-
ized (ie, based on the average TTR each center achieved in 
its warfarin-treated patients during the trial [cTTR]). In this 
Table 1. Baseline Characteristics in Relation to Quartiles of Predicted Centers’ Time in Therapeutic Range
Quartiles of Predicted Centers’ TTR*
P Value24.3–60.5 60.6–66.3 66.4–71.1 71.2–83.2
Patients randomized n=4494 n=4553 n=4602 n=4552
TTR in warfarin group
 No. (%) 2179 (48.5) 2224 (48.8) 2240 (48.7) 2226 (48.9)
 Median (Q1, Q3) 51.2 (35.6, 63.2) 62.6 (51.2, 72.4) 69.0 (58.4, 77.2) 76.6 (68.6, 83.5)
 Warfarin naive, No. (%) 2799 (62.3) 2259 (49.6) 1505 (32.7) 1237 (27.2) <0.0001
 Age, y, median (Q1, Q3) 68 (60, 74) 69 (62, 75) 71 (64, 77) 72 (66, 78) <0.0001
 Male, No. (%) 2711 (60.3) 2824 (62.0) 3039 (66.0) 3211 (70.5) <0.0001
 Weight, kg, median (Q1, Q3) 75.7 (64.0, 89.0) 80.0 (69.0, 93.0) 84.0 (71.6, 97.4) 88.1 (76.0, 102.1) <0.0001
 BP systolic, mm Hg, median (Q1, Q3) 130 (120, 140) 130 (120, 140) 130 (120, 141) 130 (120, 140) 0.0186
 BP diastolic, mm Hg, median (Q1, Q3) 80 (74, 90) 80 (72, 88) 80 (70, 87) 79 (70, 85) <0.0001
 AF type, No. (%) 0.0049
  Persistent or permanent 3822 (85.0) 3823 (84.0) 3849 (83.7) 3918 (86.1)
  Paroxysmal 672 (15.0) 729 (16.0) 752 (16.3) 633 (13.9)
 CHADS2 score, mean (SD) 2.2 (1.12) 2.1 (1.11) 2.1 (1.11) 2.0 (1.08) <0.0001
 CHADS2 category, No. (%) <0.0001
  0–1 1411 (31.4) 1528 (33.6) 1542 (33.5) 1702 (37.4)
  2 1612 (35.9) 1602 (35.2) 1660 (36.1) 1642 (36.1)
  3–6 1471 (32.7) 1423 (31.3) 1400 (30.4) 1208 (26.5)
 Age >75 y, No. (%) 842 (18.7) 1071 (23.5) 1403 (30.5) 1620 (35.6) <0.0001
 Previous stroke, No. (%) 619 (13.8) 572 (12.6) 543 (11.8) 393 (8.6) <0.0001
 Heart failure, No. (%) 1993 (44.3) 1615 (35.5) 1223 (26.6) 710 (15.6) <0.0001
 Diabetes mellitus, No. (%) 1074 (23.9) 1031 (22.6) 1157 (25.1) 1285 (28.2) <0.0001
 Hypertension, No. (%) 3886 (86.5) 4089 (89.8) 4047 (87.9) 3894 (85.5) <0.0001
 Previous MI, No. (%) 575 (12.8) 629 (13.8) 624 (13.6) 757 (16.6) <0.0001
Baseline, No. (%)
 Aspirin 1440 (32.0) 1515 (33.3) 1386 (30.1) 1291 (28.4) <0.0001
 ARB 1011 (22.5) 1028 (22.6) 1112 (24.2) 1161 (25.5) 0.0014
 ACEI/ARB 3117 (69.4) 3380 (74.2) 3239 (70.4) 3096 (68.0) <0.0001
 β-Blocker 2636 (58.7) 2821 (62.0) 2981 (64.8) 3044 (66.9) <0.0001
 Amiodarone 697 (15.5) 639 (14.0) 498 (10.8) 217 (4.8) <0.0001
 Digoxin 1657 (36.9) 1573 (34.5) 1311 (28.5) 1287 (28.3) <0.0001
 Lipid-lowering drug 1449 (32.2) 1622 (35.6) 2247 (48.8) 2881 (63.3) <0.0001
ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BP, blood pressure; MI, myocardial infarction; and 
Q, quartile.
*Centers’ time in therapeutic range (TTR) is defined in the Statistical Analysis section of Methods.
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trial and other trials, the individual factors with the largest 
impact on INR control seemed to be the processes of care at 
the site and country levels, as shown by the wide variation in 
INR control among the countries and centers, which explained 
most of the variability in TTR between the patients. However, 
to better reflect the influence of individual patient factors, we 
also used a second model that included patient-related factors 
that influenced INR control during warfarin treatment, such as 
age, sex, body weight, smoking, diabetes mellitus, experience 
of vitamin K antagonist treatment, and concomitant amioda-
rone therapy (iTTR). By using these 2 approaches, we evalu-
ated outcomes with apixaban versus warfarin in relation to 
all of the typically known information that a physician might 
use to estimate a patient’s future quality of INR control when 
anticoagulant treatment is started. The similar results of these 
rigorous predictive models (cTTR and iTTR) strongly support 
the finding that the treatment effects with apixaban compared 
with warfarin are consistent across a broad range of predicted 
TTR levels at the start of treatment.
As in previous trials,11,12 the differences in predicted TTRs 
were associated with differences in baseline characteristics, 
such as age, sex, body weight, heart failure, and warfarin 
experience, that contributed to differences in both TTR 
levels and outcomes. Thus, the observed differences in 
event rates across cTTR quartiles do not allow any causal 
interpretation because these differences were likely influenced 
by differences in socioeconomic status, healthcare systems, 
case mix, and medical treatments affecting both cTTR 
levels and outcomes. However, the comparisons between the 
randomized treatment groups within quartiles of cTTR and 
iTTR should be statistically valid because the randomization 
was stratified for center. On the basis of both models (cTTR 
Table 2. Baseline Characteristics in Relation to Quartiles of Predicted Individual Time in Therapeutic Range
Quartiles of Predicted Individual TTR*
P Value15.1–59.9 60.0–65.9 66.0–71.2 71.3–85.3
Patients randomized n=4517 n=4496 n=4633 n=4555
TTR in warfarin group
 No. (%) 2171 (48.1) 2205 (49.0) 2279 (49.2) 2213 (48.6)
 Median (Q1, Q3) 50.7 (34.0, 62.8) 62.3 (50.4, 71.9) 69.5 (59.4, 77.6) 76.6 (68.6, 83.5)
 Warfarin naive, No. (%) 3127 (69.2) 2329 (51.8) 1512 (32.6) 832 (18.3) <0.0001
 Age, y, median (Q1, Q3) 68 (59, 74) 70 (62, 75) 71 (64, 77) 71 (65, 77) <0.0001
 Male, No. (%) 2558 (56.6) 2732 (60.8) 3081 (66.5) 3414 (75.0) <0.0001
 Weight, kg, median (Q1, Q3) 75.0 (62.2, 89.9) 80.0 (69.0, 93.0) 83.9 (72.0, 97.0) 88.0 (76.9, 101.6) <0.0001
 BP systolic, mm Hg, median (Q1, Q3) 130 (120, 140) 130 (120, 140) 130 (120, 140) 130 (120, 140) 0.0923
 BP diastolic, mm Hg, median (Q1, Q3) 80 (72, 90) 80 (72, 88) 80 (70, 86) 80 (70, 85) <0.0001
 AF type, No. (%) 0.0787
  Persistent or permanent 3811 (84.4) 3775 (84.0) 3916 (84.6) 3910 (85.8)
  Paroxysmal 706 (15.6) 720 (16.0) 715 (15.4) 645 (14.2)
 CHADS2 score, mean (SD) 2.3 (1.15) 2.2 (1.11) 2.1 (1.10) 1.9 (1.00) <0.0001
 CHADS2 category, No. (%) <0.0001
  0–1 1228 (27.2) 1416 (31.5) 1538 (33.2) 2001 (43.9)
  2 1631 (36.1) 1632 (36.3) 1669 (36.0) 1584 (34.8)
  3–6 1658 (36.7) 1448 (32.2) 1426 (30.8) 970 (21.3)
 Age >75 y, No. (%) 954 (21.1) 1119 (24.9) 1421 (30.7) 1442 (31.7) <0.0001
 Previous stroke, No. (%) 659 (14.6) 561 (12.5) 559 (12.1) 348 (7.6) <0.0001
 Heart failure, No. (%) 2216 (49.1) 1637 (36.4) 1187 (25.6) 501 (11.0) <0.0001
 Diabetes mellitus, No. (%) 1228 (27.2) 1130 (25.1) 1181 (25.5) 1008 (22.1) <0.0001
 Hypertension, No. (%) 3926 (86.9) 4012 (89.2) 4097 (88.4) 3881 (85.2) <0.0001
 Previous MI, No. (%) 615 (13.6) 590 (13.1) 695 (15.0) 685 (15.0) 0.0140
Baseline, No. (%)
 Aspirin 1560 (34.5) 1495 (33.3) 1401 (30.2) 1176 (25.8) <0.0001
 ACEI/ARB 3166 (70.1) 3353 (74.6) 3256 (70.3) 3057 (67.1) <0.0001
 β-Blocker 2630 (58.2) 2842 (63.2) 3007 (64.9) 3003 (65.9) <0.0001
 Amiodarone 869 (19.2) 648 (14.4) 389 (8.4) 145 (3.2) <0.0001
 Digoxin 1694 (37.5) 1487 (33.1) 1394 (30.1) 1253 (27.5) <0.0001
 Lipid-lowering drug 1387 (30.7) 1661 (36.9) 2297 (49.6) 2854 (62.7) <0.0001
ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BP, blood pressure; MI, myocardial infarction; and 
Q, quartile.
*Individuals’ time in therapeutic range (TTR) is defined in the Statistical Analysis section of Methods.
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Figure 2. Cumulative risk of primary efficacy outcome (stroke or systemic embolism) in A, C, E, and G and primary safety outcome (major 
bleeding) in B, D, F, and H for apixaban compared with warfarin in relation to quartiles of predicted center-based international normalized 
ratio control (quartile 1: centers’ time in therapeutic range [cTTR] ≤60.5%; quartile 2: cTTR 60.6–66.3%; quartile 3: cTTR 66.4–71.1%; 
quartile 4: cTTR ≥71.2%).
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and iTTR), reductions in stroke or systemic embolism with 
apixaban compared with warfarin were maintained regardless 
of the predicted quality of INR control. Similar indications of 
persistent benefits have been seen with another new alternative 
agent to warfarin.12 There was also a maintained advantage 
with apixaban over warfarin in terms of major bleeding across 
all center and patient characteristics that predicted levels of 
INR control. This is the first time that simultaneous benefits 
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Figure 3. Outcome with apixaban vs warfarin in relation to quartiles of predicted centers’ time in therapeutic range (cTTR). The interaction 
test was based on the continuous cTTR and restricted cubic spline for nonlinearity. The primary efficacy outcome was stroke (ischemic, 
hemorrhagic, or unspecified) or systemic embolism (SSE). Major bleeding was the primary safety outcome. Net clinical benefit was the 
composite of SSE, all-cause death, and major bleeding. CI indicates confidence interval; and HR, hazard ratio.
Figure 2. Continued
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have been reported in the reduction of both stroke and bleeding 
events and in net clinical benefit by a novel agent versus 
warfarin regardless of the predicted quality of INR control.
These analyses have several limitations. Whereas the esti-
mation of outcome in relation to cTTR was prespecified, the 
model in relation to iTTR was performed as a post hoc sen-
sitivity analysis. The estimates of quality of INR control by 
cTTR and iTTR have the weakness of being based on post-
randomization data. However, the predictions involved only 
baseline data that allowed groups to be defined and compared 
from the point of treatment initiation. As with all models, 
we are limited to studying measured covariates. Thus, our 
results are robust as long as we have collected the primary 
determinants of TTR that are regularly known at baseline. 
There are also relationships between both cTTR and iTTR 
and standards of care that make it difficult to draw conclu-
sions regarding those factors that eventually might modulate 
the treatment effects. However, when one focuses on the 
question of whether centers or patients with better predicted 
INR control, through either favorable patients or better care 
or both, can expect similar results with apixaban compared 
with warfarin, as in the overall trial, it is not necessary to 
determine causal mechanisms. Finally, despite lack of sta-
tistical significance, there are trends toward attenuation of 
the treatment effects at centers and in patients with predicted 
excellent INR control in which interaction tests are less reli-
able because of low numbers of events and therefore lack of 
statistical power.
Conclusions
The benefits of apixaban over warfarin in preventing stroke, 
reducing all types of bleeding, and improving survival appear 
to be maintained regardless of centers’ and patients’ predicted 
quality of INR control. Therefore, in patients with AF and at 
least 1 additional risk factor for stroke, apixaban seems to be 
a more effective and safer treatment than warfarin across a 
broad range of quality of warfarin management.
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       N
74 (1.85)
59 (1.45)
38 (0.90)
41 (0.92)
179 (4.35)
180 (4.29)
144 (3.35)
100 (2.22)
54 (1.48)
78 (2.09)
103 (2.67)
92 (2.25)
263 (6.69)
282 (7.09)
269 (6.59)
229 (5.34)
113 (3.17)
120 (3.29)
131 (3.47)
127 (3.17)
   Events (%/yr)
2238
2262
2339
2242
2238
2262
2339
2242
2235
2250
2330
2237
2238
2262
2339
2242
2238
2262
2339
2242
              Warfarin 
      N
102 (2.67)
66 (1.58)
52 (1.21)
45 (1.06)
201 (5.03)
187 (4.37)
173 (3.93)
108 (2.50)
106 (3.09)
114 (3.07)
118 (3.05)
124 (3.15)
334 (8.97)
310 (7.68)
311 (7.50)
258 (6.27)
174 (5.24)
159 (4.36)
154 (4.07)
154 (3.99)
  Events (%/yr)
0.70 (0.52-0.94)
0.92 (0.65-1.30)
0.74 (0.49-1.13)
0.87 (0.57-1.33)
0.87 (0.71-1.06)
0.98 (0.80-1.21)
0.85 (0.68-1.06)
0.89 (0.67-1.16)
0.48 (0.35-0.67)
0.68 (0.51-0.91)
0.87 (0.67-1.14)
0.73 (0.55-0.94)
0.75 (0.64-0.88)
0.92 (0.79-1.09)
0.88 (0.74-1.03)
0.85 (0.71-1.02)
0.61 (0.48-0.78)
0.75 (0.60-0.96)
0.85 (0.67-1.07)
0.79 (0.63-1.00)
HR (95% CI)
0.060
0.67
0.078
0.85
0.34
P Interaction
0.3        0.4    0.5   0.6       0.8                                   2
Figure 4. Outcome with apixaban vs warfarin in relation to quartiles of predicted individual time in therapeutic range (iTTR). The 
interaction test was based on the continuous iTTR. The primary efficacy outcome was stroke (ischemic, hemorrhagic, or unspecified) 
or systemic embolism (SSE). Major bleeding was the primary safety outcome. Net clinical benefit was the composite of SSE, all-cause 
death, and major bleeding. CI indicates confidence interval; and HR, hazard ratio.
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CLINICAL PERSPECTIVE
 Warfarin effectively prevents stroke in patients with atrial fibrillation but has a narrow therapeutic window with an increased 
risk of stroke and bleeding when above or below the time in therapeutic range (TTR) of international normalized ratio of 
2.0 to 3.0. There are large variations of TTR across individuals, sites, and countries, which are related to patient outcomes. 
The global Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial 
randomized 18 201 patients with atrial fibrillation in 1034 centers in 39 countries to apixaban or warfarin at a median TTR of 
66% but with substantial variation between countries, centers, and patients. The overall results showed that apixaban reduced 
stroke by 21%, death by 11%, and major bleeding by 31%. Key additional questions involved the extent of benefits that re-
mained in centers with higher TTR. The challenge in determining this issue is the lack of a comparable measure of the level 
of anticoagulation in both the apixaban and warfarin arms. We developed a new method in which, for each patient, a center 
average TTR was estimated with the use of a linear mixed model based on real TTRs in the warfarin-treated patients, with a 
fixed effect for country and random effect for center. For each patient, an individual TTR was also predicted with the use of 
a linear mixed effects model including patient characteristics as well. The results of these analyses consistently showed that 
the benefits of apixaban compared with warfarin for stroke or systemic embolism, bleeding, and mortality appeared similar 
across the range of centers’ and patients’ predicted quality of international normalized ratio control.
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Supplemental Figure 1 
The variability in center based TTR (cTTR) by country with cTTR predicted according to the mixed model with a fixed 
effect for country and random effect for center (Countries with less than 10 sites were excluded to simplify the plot). 
 
  
Short title: Apixaban in relation to predicted INR control 
 3 
Supplemental Figure 2  
Correlation between predicted individual TTR (iTTR) and predicted center based TTR (cTTR)  
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Supplemental Table 1 
 
Endpoints by predicted Center TTR (cTTR) for Vitamin K Antagonist (VKA) experienced patients 
 
                                                                                               Apixaban 
                                                Apixaban                           Warfarin      vs.                   Interaction 
                         Apixaban   Apixaban    Rate/100    Warfarin   Warfarin    Rate/100    Warfarin                   (RCS) 
Predicted Center TTR        N        Events    person yrs      N        Events    person yrs      HR        95% CI       p-value 
 
                                                                                                                                   
Primary Outcome                                                                                                           0.065    
  24.3-60.5                 836        23         1.57         859        36         2.42        0.65     0.38, 1.09               
  60.6-66.3                1147        24         1.13        1147        33         1.56        0.73     0.43, 1.23               
  66.4-71.1                1554        21         0.76        1543        43         1.60        0.47     0.28, 0.80               
  71.2-83.2                1671        34         1.08        1644        26         0.84        1.29     0.78, 2.15               
                                                                                                                                   
Total Death                                                                                                               0.19     
  24.3-60.5                 836        57         3.77         859        61         3.96        0.95     0.66, 1.36               
  60.6-66.3                1147        73         3.38        1147        72         3.34        1.01     0.73, 1.40               
  66.4-71.1                1554        86         3.06        1543       115         4.17        0.73     0.55, 0.97               
  71.2-83.2                1671        83         2.61        1644        88         2.81        0.93     0.69, 1.26               
                                                                                                                                   
Primary Safety Outcome                                                                                                    0.56     
  24.3-60.5                 833        18         1.31         855        32         2.31        0.57     0.32, 1.01               
  60.6-66.3                1146        32         1.61        1145        60         3.08        0.52     0.34, 0.80               
  66.4-71.1                1548        64         2.53        1541        78         3.22        0.79     0.57, 1.10               
  71.2-83.2                1669        71         2.47        1639       104         3.64        0.68     0.50, 0.92               
                                                                                                                                   
Net Clinical Benefit                                                                                                      0.49     
  24.3-60.5                 836        81         5.60         859       102         6.99        0.80     0.60, 1.07               
  60.6-66.3                1147       123         5.93        1147       144         7.03        0.85     0.66, 1.08               
  66.4-71.1                1554       166         6.19        1543       207         7.97        0.78     0.63, 0.95               
  71.2-83.2                1671       186         6.18        1644       205         6.88        0.90     0.74, 1.09               
                                                                                                                                   
SSE or Major Bleeding                                                                                                     0.30     
  24.3-60.5                 836        36         2.68         859        59         4.37        0.61     0.41, 0.93               
  60.6-66.3                1147        52         2.68        1147        82         4.32        0.62     0.44, 0.88               
  66.4-71.1                1554        81         3.27        1543       106         4.49        0.73     0.55, 0.97               
  71.2-83.2                1671       101         3.59        1644       119         4.24        0.84     0.65, 1.10                 
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Supplemental Table 2 
 
Endpoints by predicted Individual TTR (iTTR) for Vitamin K Antagonist (VKA) experienced patients 
 
                                                                                               Apixaban 
                                                Apixaban                           Warfarin      vs.                   Interaction 
                         Apixaban   Apixaban    Rate/100    Warfarin   Warfarin    Rate/100    Warfarin                   (RCS) 
Predicted iTTR              N        Events    person yrs      N        Events    person yrs      HR        95% CI       p-value 
 
                                                                                                                                   
Primary Outcome                                                                                                           0.080    
  15.1-59.9                1582        53         1.91        1545        67         2.53        0.76     0.53, 1.08               
  60.0-65.9                1169        40         1.84        1160        35         1.60        1.14     0.73, 1.80               
  66.0-71.2                 734        11         0.77         778        15         0.97        0.78     0.36, 1.71               
  71.3-85.3                 427         6         0.69         405        10         1.22        0.57     0.21, 1.58               
                                                                                                                                   
Total Death                                                                                                               0.89     
  15.1-59.9                1582       130         4.55        1545       144         5.20        0.87     0.69, 1.11               
  60.0-65.9                1169       101         4.48        1160       108         4.82        0.93     0.71, 1.22               
  66.0-71.2                 734        51         3.48         778        58         3.71        0.94     0.64, 1.37               
  71.3-85.3                 427        22         2.49         405        23         2.76        0.90     0.50, 1.62               
                                                                                                                                   
Primary Safety Outcome                                                                                                    0.22     
  15.1-59.9                1574        42         1.68        1544        75         3.20        0.53     0.36, 0.77               
  60.0-65.9                1164        49         2.48        1151        63         3.31        0.75     0.52, 1.09               
  66.0-71.2                 728        39         3.04         773        36         2.66        1.14     0.72, 1.79               
  71.3-85.3                 426        12         1.49         404        14         1.87        0.80     0.37, 1.73               
                                                                                                                                   
Net Clinical Benefit                                                                                                      0.86     
  15.1-59.9                1582       195         7.16        1545       237         9.22        0.78     0.65, 0.94               
  60.0-65.9                1169       161         7.56        1160       168         7.97        0.95     0.76, 1.18               
  66.0-71.2                 734        94         6.87         778       108         7.38        0.93     0.70, 1.22               
  71.3-85.3                 427        37         4.38         405        42         5.28        0.83     0.53, 1.29               
                                                                                                                                   
SSE or Major Bleeding                                                                                                     0.53     
  15.1-59.9                1582        83         3.41        1545       117         5.16        0.67     0.50, 0.89               
  60.0-65.9                1169        76         3.94        1160        87         4.65        0.85     0.62, 1.15               
  66.0-71.2                 734        45         3.57         778        48         3.62        0.98     0.65, 1.48               
  71.3-85.3                 427        17         2.15         405        23         3.14        0.69     0.37, 1.29               
 
 
